Hims & Hers Health launches lab testing with Quest Diagnostics - DJ

Published 13/11/2025, 17:54
© Reuters.

Investing.com -- Hims & Hers Health is expanding into lab testing services as part of its growing focus on preventive healthcare, according to Dow Jones.

The telehealth platform will allow customers to access testing at more than 1,000 Quest Diagnostics locations nationwide. After testing, users will receive results and consult with providers on the Hims & Hers platform to develop personalized health plans that may include prescriptions, supplements, or nutrition guidance.

The company offers two pricing tiers: a $199 annual plan for one blood draw covering 50 biomarker tests, and a $499 plan that includes two blood draws and 120 biomarker tests. These tests evaluate various health aspects including heart health, metabolism, hormones, inflammation, and stress.

Chief Executive Andrew Dudum believes the service will be accessible to most Americans. "It’s a price point that I think the majority of the country can afford," he said.

Dudum expects this preventive care initiative to attract new users beyond the company’s established customer base for hair loss, weight loss, and sexual health treatments. He projects the lab testing service will eventually grow into a $1 billion business.

"You know, size of this market is, I think every single person in the country," Dudum stated regarding the potential reach of the new offering.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.